Correlation Between Biocardia and BioNTech
Can any of the company-specific risk be diversified away by investing in both Biocardia and BioNTech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biocardia and BioNTech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Biocardia and BioNTech SE, you can compare the effects of market volatilities on Biocardia and BioNTech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biocardia with a short position of BioNTech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biocardia and BioNTech.
Diversification Opportunities for Biocardia and BioNTech
Very weak diversification
The 3 months correlation between Biocardia and BioNTech is 0.44. Overlapping area represents the amount of risk that can be diversified away by holding Biocardia and BioNTech SE in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on BioNTech SE and Biocardia is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biocardia are associated (or correlated) with BioNTech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of BioNTech SE has no effect on the direction of Biocardia i.e., Biocardia and BioNTech go up and down completely randomly.
Pair Corralation between Biocardia and BioNTech
Given the investment horizon of 90 days Biocardia is expected to under-perform the BioNTech. In addition to that, Biocardia is 1.74 times more volatile than BioNTech SE. It trades about -0.18 of its total potential returns per unit of risk. BioNTech SE is currently generating about -0.1 per unit of volatility. If you would invest 12,076 in BioNTech SE on September 25, 2024 and sell it today you would lose (663.00) from holding BioNTech SE or give up 5.49% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Biocardia vs. BioNTech SE
Performance |
Timeline |
Biocardia |
BioNTech SE |
Biocardia and BioNTech Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Biocardia and BioNTech
The main advantage of trading using opposite Biocardia and BioNTech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biocardia position performs unexpectedly, BioNTech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioNTech will offset losses from the drop in BioNTech's long position.Biocardia vs. Aerovate Therapeutics | Biocardia vs. Adagene | Biocardia vs. Acrivon Therapeutics, Common | Biocardia vs. Rezolute |
BioNTech vs. Novavax | BioNTech vs. Ginkgo Bioworks Holdings | BioNTech vs. Crispr Therapeutics AG | BioNTech vs. Ocean Biomedical |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Stocks Directory Find actively traded stocks across global markets | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |